microdosing semaglutide benefits of GLP-1 GLP-1 (glucagon-like peptide-1) receptor agonists, such as tirzepatide (Zepbound) or (Ozempic, Wegovy), are typically prescribed for diabetes and obesity management at standard therapeutic doses. Microdosing 🚨 Today, retatrutide, the Base-Product Weekly Dose:1 mg

microdosing semaglutide benefits of GLP-1 GLP-1 (glucagon-like peptide-1) receptor agonists, such as tirzepatide (Zepbound) or (Ozempic, Wegovy), are typically prescribed for diabetes and obesity management at standard therapeutic doses. Microdosing 🚨 Today, retatrutide, the Base-Product Weekly Dose:1 mg

🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️

In Trial 1, eligible patients were randomized to either setmelanotide or placebo and entered an up to 8-week dose titration period followed by a 52-week treatment period

Base-Product

Weekly Dose:1 mg

Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans